Navigation Links
BioMarin Announces IND for BMN-111 for Achondroplasia is Active
Date:1/3/2012

NOVATO, Calif., Jan. 3, 2012 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Investigational New Drug (IND) application for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia is active.  The company expects to initiate the Phase 1 trial in the first quarter of 2012.

"BMN-111 has demonstrated benefits in moderately and severely affected animal models and has been shown to promote bone growth even in normal animals," stated Hank Fuchs, M.D., Chief Medical Officer of BioMarin.  "BMN-111 will mark our seventh program in the clinic, the most ever in the history of the company.  We look forward to many potentially value-creating clinical milestones in the coming year."

The primary objective of the Phase 1 trial is to assess the safety and tolerability of single and multiple doses of BMN-111 in normal adult healthy volunteers up to the maximum tolerated dose.  The company expects to start the Phase 2 study in pediatric subjects in the fourth quarter of 2012 or the first quarter of 2013.

About AchondroplasiaAchondroplasia is caused by an autosomal dominant activating mutation in the fibroblast growth factor receptor 3 (FGFR3) gene, a negative regulator of bone growth. Eighty percent of cases are the result of a spontaneous mutation, and ninety-eight percent of those cases have a G380R mutation. Achondroplasia is the most common form of human dwarfism and is characterized by failure of normal conversion of cartilage into bone. Clinical manifestations of the disease include short stature, craniomedullary compression, apnea, bowed legs, frontal bossing and midface hypoplasia, permanent sway of the lower back, spinal stenosis, recurrent ear infections and obesity.

The rate of incidence of achondroplasia is one in 15,000 to one in 40,000 live births, with approximately 18,000 to
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility
2. Highlights from BioMarins Research & Development Day
3. BioMarin Announces Buy Back of Naglazyme Royalties From Adelaide Health Authority
4. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
5. BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
6. BioMarin to Host a Research and Development Day on December 8th
7. BioMarin Announces Third Quarter 2011 Financial Results
8. BioMarin to Present at the UBS Global Life Sciences Conference
9. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
10. BioMarin to Present at the Baird Health Care Conference
11. BioMarin to Present at the Wedbush Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... and NEW YORK , June ... Company) (NYSE: BDX ) are accelerating the development ... glucose sensing technologies through a new collaboration announced today. This ... focused on type 1 diabetes (T1D). Many patients ... pump – requiring a catheter to be placed in the ...
(Date:6/18/2013)... EMERYVILLE, Calif. , June 18, 2013 ... today from a Phase 2/3 clinical trial of ... statistically significant improvement in levodopa-induced dyskinesia (LID) as ... versus placebo in the Unified Dyskinesia Rating Scale ... amantadine intended for once-nightly administration that is being ...
(Date:6/17/2013)... June 17, 2013 Velplex, LLC announced this ... technology platform that connects buyers and sellers of ... industry leader. Why? It,s because the ... intimately familiar with the dental industry. They have 50 ... have diligently worked to negotiate some of the best ...
Breaking Medicine Technology:JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 2JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6TopProdeals.com Rises to Top as Discount Dental Supply Leader 2
... N.J., Nov. 3, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... and nine months ended September 30, 2011, which reflect the ... Savient ended the quarter with $202.7 million in cash and ...  For the third quarter of 2011, the Company had a ...
... of Pharmaceutical and Biotech Trainers ( SPBT ) today announced ... Board of Directors, effective January 1, 2012.  She brings to ... management development, sales, and marketing. A valuable SPBT ... president of the SPBT Board since 2006.  In her new ...
Cached Medicine Technology:Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 7Carol Wells Elected President of the Society of Pharmaceutical and Biotech Trainers 2
(Date:6/18/2013)... June 19, 2013 Looking for a way ... of everyday life? , IWALKAWAKE is a guide to ... by Adam Botha, it focuses on harnessing the powerful and ... book lays out a nine-step guide to finding one’s true ... a person must go through to reach their true potential. ...
(Date:6/18/2013)... 2013 The Drug Delivery Partnering Terms ... to the drug delivery partnering deals and agreements entered ... The report provides a detailed understanding and analysis of ... The majority of deals are discovery or development stage ... right to license the license drug delivery technology. These ...
(Date:6/18/2013)... 18, 2013 Palo Alto has taken yet ... greenest cities with its recent major long-term solar power commitment. ... major solar electric power purchase agreements , which together will ... of solar photovoltaic electric power per year, which is the ... That’s enough power to supply all 65,000+ Palo Alto ...
(Date:6/18/2013)... research has shown that cancer cells have a much ... cells. Now, scientists at The University of Texas at ... a new strategy to combat lung cancer. , In ... PLOS ONE , UT Dallas researchers compared the ... lung cells taken from the same patient. , ...
(Date:6/18/2013)... Los Angeles, CA (PRWEB) June 18, 2013 ... article entitled “The Cheater’s Guide to Getting Beach Ready,” offers ... women ready to look their best in a bathing suit ... marks , skin firming , smoothing cellulite , ... says Dr. Simon Ourian, Medical Director of Epione Beverly Hills, ...
Breaking Medicine News(10 mins):Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:Skin Care – Getting Your Body Beach Ready 2
... of Nottingham say our stress levels at work peak when we ... we head towards retirement. In the first comprehensive report ... out in Britain researchers from the Institute of Work, Health and ... lives can stay with us well into retirement. The research, ...
... Acne scars and wrinkles benefit from more aggressive treatment, ... Rough buffing of the skin does a better job ... than a gentler rubbing, University of Michigan researchers report. ... popular way to improve the appearance of wrinkles, acne ...
... Schein, Inc. (Nasdaq: HSIC ) announced today that it ... stock market opens on Wednesday, November 4, 2009, and will ... the same day beginning at 10 a.m. Eastern Standard Time. ... Chairman and Chief Executive Officer of Henry Schein, and Steven ...
... ... announce that it has made another significant commitment to environmental sustainability by joining Practice ... engaged in reducing their environmental footprints. , ... Irvine, CA (PRWEB) October 21, 2009 -- Vestara, provider of ...
... ... premium rates for every major insurer in every county in every state. This year,s ... some instances , ... Chicago, IL (PRWEB) October 21, 2009 -- Rates for physicians, 2009-2010 liability insurance premiums ...
... ... Cytoscape databases enable researchers to quickly and effectively use these invaluable resources. , ... Seattle, WA (PRWEB) August ... suite on Pathway Interaction Database (PID), and new tutorials on BiologicalNetworks, and Cytoscape. ...
Cached Medicine News:Health News:Older workers are the healthy 'survivors' of the workplace 2Health News:With Microdermabrasion, Rough Seems to Work Better 2Health News:With Microdermabrasion, Rough Seems to Work Better 3Health News:Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday, November 4, at 10 A.M. EST 2Health News:Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 2Health News:Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 3Health News:Medical Liability Monitor Annual Survey of Medical Malpractice Insurance Rates Shows Medical Liability Insurance Market Remains Soft 2Health News:New and Updated Online Tutorials for PID, BiologicalNetworks, and Cytoscape 2Health News:New and Updated Online Tutorials for PID, BiologicalNetworks, and Cytoscape 3
... display and IOL power calculation software. ... firmware module with SRKII, SRKT, Holladay Dioptimum ... increase in frequency the closer you get ... is achieved with corneal indentation. Triple tone ...
The CryoSurgery console is the control center for CryoCath's surgical probe. It is a modular system made up of a console control unit and a tank dolly system. The system can be used as a unit or in s...
... SurgiFrost is a malleable, single-use cryosurgical probe ... surgery. The probe will ablate cardiac tissue ... cardiac surgical procedure, such as coronary artery ... replacement and/or repair and as part of ...
The Medtronic CardioRhythm Marinr Catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing a...
Medicine Products: